Ask AI
ProCE Banner Activity

ALEXANDRA/IMpassion030: Phase III Trial of Adjuvant Chemotherapy ± Atezolizumab for Stage II/III Triple-Negative Breast Cancer

Conference Coverage
Slideset

In patients with early-stage triple-negative breast cancer, the addition of atezolizumab to adjuvant chemotherapy did not improve iDFS over chemotherapy alone, according to results of the phase III ALEXANDRA/IMpassion030 trial.

Released: December 08, 2023

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc., Gilead Sciences, Inc., Lilly, Merck Sharp & Dohme LLC, and Seagen Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.

Lilly

Merck Sharp & Dohme, LLC

Seagen Inc.